Sector News

Inositec names ex-Roche, Novartis staffer as CMO

January 19, 2018
Life sciences

Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.

Zurich, Switzerland-based Inositec hired van Alphen away from Roche, where he led the operational excellence team. Earlier in his career, van Alphen worked as CMO of Vifor Pharma and headed up European medical affairs at Novartis. The Novartis role also gave van Alphen responsibility for leading the company’s clinical operations team in the Netherlands. Van Alphen will now use this experience to guide Inositec into and through the clinic.

Inositec spun out of ETH Zurich late in 2015 to develop drugs based on inositol hexaphosphate. The biotech has a platform capable of replacing phosphate groups on the molecule with a view to giving them druglike properties. Inositec sees the small molecules treating a range of conditions. Vascular calcification is top of its hit list.

The small molecules advancing down the pipeline at Inositec are designed to inhibit pathological crystallization in soft tissues and thereby prevent the stiffening and blockage of arteries. If the R&D strategy goes according to plan, the drugs will have these effects regardless of the root cause of the vascular calcification, making them suitable for use in all calcification-dependent cardiovascular diseases.

Inositec is some way from clinically validating its belief in this mechanism. But with van Alphen in the CMO seat, it has taken another step toward generating supportive data.

“Dr. van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” Inositec CEO Mattias Ivarsson, Ph.D., said in a statement.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).